Teva receives positive CHMP opinion on clopidogrel / acetylsalicylic acid The Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of a marketing authorization for the medicinal product Clopidogrel/Acetylsalicylic acid Teva. The applicant for this medicinal product is Teva Pharma. Reference Link
Teva board authorizes increase in share repurchase program to $3B The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.